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Myeloid Leukemia Outcomes after Umbilical Cord
Blood Transplantation
Betul Oran,1,2 John E.Wagner,1,3 Todd E. DeFor,1 Daniel J.Weisdorf,1,2 Claudio G. Brunstein1,2Reduced-intensity conditioning (RIC) umbilical cord blood (UCB) transplantation is increasingly used in
hematopoietic stem cell transplantation (HCT) for older and medically unfit patients. Data on the efficacy
of HCTafter RIC relative to myeloablative conditioning (MAC) are limited. We compared the outcomes of
acute myeloid leukemia (AML) patients.18 yrs who receivedUCB grafts after either RIC orMAC.One hun-
dred nineteen adult patients with AML in complete remission (CR) underwent an UCB transplant after RIC
(n 574, 62%) or MAC (n 5 45, 38%) between January 2001 and December 2009. Conditioning was either
reduced intensity and consisted of cyclophosphamide 50 mg/kg, fludarabine 200 mg/m2, and total-body irra-
diation (TBI) 200 cGy or myelablative and consisted for cyclophosphamide 120 mg/kg, fludarabine 75 mg/m2,
and TBI 1200-1320 cGy. All patients received cyclosporine (day23 to day1180) and mycophenolate mofetil
(day 23 to day 145) post-HCT immunosuppression and hematopoietic growth factor. Use of RIC was re-
served for patients.45 years (n5 66, 89%) or preexisting severe comorbidities (n5 8, 11%). The 2 groups
were similar except for preceding myelodysplastic syndrome (RIC5 28% versus MAC5 4%, P\.01) and age
that was dictated by the treatment protocols (median, RIC5 55 years versus MAC5 33years; P\.01). The
incidence of neutrophil recovery at day142 was higher with RIC (94% versus MAC5 82%, P\.1), whereas
platelet recovery at the sixth month was similar (RIC5 68% versus MAC5 67%, P5.30). Incidence of grade
II-IV acute graft-versus-host disease (aGVHD) (RIC5 47% versus MAC5 67%, P\.01) was decreased with
similar incidence of chronic GVHD (cGVHD) (RIC5 30% versus MAC5 34%, P5.43). Median follow-up for
survivors was 3.8 and 4.5 years for RIC and MAC, respectively (P5 .4). Using RIC, 3-year leukemia-free sur-
vival (LFS) was decreased (31% versus MAC5 55%, P5.02) and 3-year relapse incidence was increased (43%
versus MAC 5 9%, P\.01). Two-year transplant-related mortality (TRM) was similar (RIC 5 19% versus
MAC 5 27%; P 5 .55). In multivariate analysis, RIC recipients and those in CR2 with CR1 duration
\1 year had higher risk of relapse and poorer LFS with no independent predictors of TRM. UCB with RIC
extends the use of allogeneic HCT for older and frail patients without excessive TRM with greater benefit
for patients in CR1 and CR2 with longer CR1.
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6/j.bbmt.2011.01.007tentially curative treatment for patients with acute
myelogenous leukemia (AML) [1,2]. However, MAC
is associated with significant regimen-related toxicity
(RRT) and risk of transplant-related mortality (TRM).
The introduction of reduced-intensity conditioning
(RIC) has extended allogeneic transplantation to older
and less medically fit patients by reducing RRT [3,4].
RICrelies largelyongraft-versus leukemia (GVL)effect
of the immunocompetent cells in the graft, rather than
the high-dose chemotherapy for the antitumor effect
[1,5-7].
Unrelated umbilical cord blood (UCB) has
emerged as an alternative source for HCT and may
be particularly valuable patients who have a narrow
time window of opportunity to proceed to transplanta-
tion [8]. Recent studies have demonstrated similar
leukemia-free survival (LFS) after UCB and unrelated1327
1328 Biol Blood Marrow Transplant 17:1327-1334, 2011B. Oran et al.donor (URD) transplantation after MAC in patients
with acute leukemia [9-13]. Our group has reported
high rates of engraftment, low TRM, and promising
event-free survival (EFS) for hematologicmalignancies
with UCB even after RIC HCT [14].
Although there are limited data comparing the
outcomes after RIC and MAC [15-18], none include
UCB recipients. Thus, we retrospectively studied the
outcomes in adults with AML patients in complete
remission (CR) who underwent UCB transplantation
after MAC or RIC regimens.PATIENTS AND METHODS
Patients
Patients$18 years with AML in first (CR1) or sec-
ond (CR2) morphologic complete remission, defined
by the presence of\5% blasts in the bone marrow,
transplanted with unrelated UCB between January
2001 and December 2009, were included in this study.
This time period was chosen so that recipients of a RIC
and MAC regimens were offered uniform supportive
care. Patients with a prior diagnosis of myelodysplastic
syndrome (MDS) and myeloproliferative disorders
(MPD) were included only if they had progressed to
AML, were treated, and achieved a CR. Treatment
protocols and retrospective analysis were approved
by the institutional review board (IRB) of the Univer-
sity of Minnesota and registered at www.clinicaltrials.
gov under numbers NCT00305682, NCT00365287,
NCT00290641, and NCT0030984. All patients pro-
vided written informed consent in accordance with
the Declaration of Helsinki. UCB unit selection has
been detailed elsewhere [14,19]. In 86% the graft
consisted of 2 UCB units to achieve a combine cell
dose $2.5  107/kg. All UCB units were thawed
according to the methods of Rubinstein et al. [20].
Treatment Plan and Supportive Care
Seventy-four patients received an RIC regimen
consisting of fludarabine (40 mg/m2 intravenously
daily for 5 days) and 200 cGy total-body irradiation
(TBI) with cyclophosphamide (50 mg/kg intrave-
nously for 1 day) [14]. Twenty-two of 74 RIC (30%)
patients received equine antithymocyte globulin
(ATG, ATGAM; Pharmacia, Kalamazoo, MI) 15 mg/
kg every 12 hours for 3 days as part of the conditioning
regimen for patients considered at high risk for graft
rejection [14]. Forty-five patients received aMAC reg-
imen consisting of cyclophosphamide (60 mg/kg intra-
venously daily for 2 days), 1320 cGy TBI given divided
in 8 fractions and fludarabine (25 mg/m2 daily for 3
days) [19]. ATG was not given to MAC patients.
Graft-versus-host disease (GVHD) prophylaxis con-
sisted of cyclosporine (days –3 to at least 1100) and
mycophenolate mofetil (days –3 to at least 130).Granulocyte-colony stimulating factor (G-CSF) (5
mg/kg per day) was administered to all patients from
day 11 until an absolute neutrophil count (ANC) of
2.5  109/L or higher was achieved for 2 consecutive
days. All patients received fluconazole or voriconazole
for prophylaxis of fungal infections for 100 days and
trimethoprim-sulfamethoxazole for prophylaxis of
Pneumocystis jiroveci after engraftment for 12months af-
ter transplantation and extended spectrum fluoroqui-
nolones for prophylaxis of Gram-positive organisms
during treatment of GVHD. Viral prophylaxis in-
cluded acyclovir if seropositive for herpes simplex or
cytomegalovirus (CMV) before transplantation.
CMV surveillance was performed weekly with ganci-
clovir treatment at the time of positive antigenemia
or polymerase chain reaction (PCR) testing. Chime-
rism was determined by quantitative PCR of informa-
tive polymorphic variable number tandem repeat
(VNTR) or short tandem repeat (STR) regions in the
recipient and donor as described [19].
Endpoints and Definitions
The primary study endpoint was LFS defined as
survival without disease relapse. Patients were cen-
sored at the time of death, relapse, or last follow-up.
Other study endpoints included cumulative incidences
of relapse, TRM, neutrophil recovery, platelet recov-
ery, acute and chronic GVHD (aGVHD, cGVHD).
Relapse was defined as disease recurrence at any site.
TRM was defined as death because of causes other
than leukemia relapse. Time to neutrophil engraft-
ment was measured from the date of transplantation
to the date of recovery (defined as the first of 3 consec-
utive days of ANC $5  109/L), with exclusion for
early death (ie, death before day 21 without neutrophil
recovery). Patients who had no engraftment by day 42
were treated as graft failures. Time to platelet engraft-
ment was defined as a count higher than 50 109/L for
the first of 7 days without platelet transfusion support.
For double UCB recipients, the cell doses (nucleated
cells, CD341 and CD31) were reported as the com-
bined dose of the UCB donor units, and HLA and
ABO matching were defined by the worst matched of
the 2 units. Comorbidities were scored according to
the Hematopoietic Cell Transplantation Specific Co-
morbidity Index (HCT-CI) [21]. Diagnostic cytoge-
netics were classified by Southwest Oncology Group
(SWOG) [22] or by presence of monosomal karyotype
[23].
Statistical Considerations
Patient and transplant characteristics by condition-
ing intensity were compared using the chi-square test
for categoric data and the Wilcoxon rank-sum test for
continuous data. LFS was calculated using the
Kaplan-Meier method [24]. Univariate comparisons
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Cumulative incidence was used to estimate the end-
points of hematopietic recovery, relapse, TRM, and
aGVHD and cGVHD [26]. A Cox proportional haz-
ards model [27] or the Fine & Gray method [28] for
competing hazardswas used formultivariate regression
of LFS and incidences of relapse and TRM, respec-
tively. Variables included in the models were the num-
ber of donor UCB units (1 versus 2), maximum HLA
disparity, ABO compatibility, CMV serostatus, disease
status at transplantation (CR1 versus CR2 with CR1
duration\1 year (CR2w/CR1\1y) versus CR2 with
CR1 duration $1 year (CR2w/CR1$1y), diagnostic
cytogenetics by SWOG (favorable, intermediate, and
unfavorable), HCT-CI, and conditioning regimen.
All factors were tested for the proportional hazards as-
sumption.The conditioning regimen anddisease status
were included in each model. Age was not included in
themodels as it was highly correlated with the assigned
intensity of the conditioning regimen. Analyses were
performed using SAS 9.2 (SAS Institute, Cary, NC).RESULTS
Patient and Grafts Characteristics
Patient characteristics of the 119 eligible patients
are shown in Table 1. The 2 groups were similar for
patient and graft characteristics except for age, as age
.45 years (n5 66) were only eligible for RIC. Median
age at transplantation was 55 years for RIC and 33
years for MAC group (P \ .01). Forty-eight of 74
RIC patients (65%) and 25 of 45 MAC (56%) were
in CR1 (P 5 .31) and the remaining patients were in
CR2 at UCB transplantation. Twenty-five of 46 pa-
tients in CR2 (54%) had CR1 duration\1 year, and
this was similarly distributed in both groups (P 5 .9).
Detailed results of diagnostic cytogenetic data were
available in 115 patients. Thirty RIC (41%) and 17
MAC (38%) patients (P 5 .14) had unfavorable risk
karyotype [22]. However, RIC patients had a higher
frequency of monosomal karyotype (MK, 11% versus
2%, P 5 .06), which has been shown to carry a poor
prognosis [23,29]. The HCT-CI scores at the time
of transplantation were similar for the 2 groups with
37 RIC (50%) and 17 MAC (40%) patients having
a score $3 (P 5 .13). Total nucleated (TNC),
CD341 and CD31 cell doses were similar for the 2
treatment groups. The majority of patients received
a transplant of 2 partially HLA-matched UCB units.
Donor-recipient HLA disparity was similar between
groups.LFS
Point estimates of clinical outcomes are summa-
rized inTable 2. The probability of LFS at 3 years afterRIC was 31% (95% confidence interval [CI], 21%-
43%) and after MAC 55 %(95% CI, 41%-70%)
(Figure 1A). Forty-eight of 74 patients (65%) with
RIC and 19 of 45 (42%) patients with MAC relapsed
or died with a median time of 0.7 years in the RIC
group. The median LFS was not reached after MAC.
Considering all patients, the LFS for patients in CR1
was 43% (95% CI, 31%-54%), in CR2w/CR1\1y
was 26% (95% CI, 10%-45%) and in CR2w/
CR1$1y was 54% (95% CI, 30%-73%). When the
analysis was limited to recipients of MAC the LFS
for patients transplanted in CR1 was 52% (95% CI,
31%-69%), in CR2w/CR1\1y was 61% (95% CI,
27%-84%), and in CR2w/CR1$1y was 65% (95%
CI, 25%-87%) (Figure 1B). In contrast, LFS after
RIC was 38% (95% CI, 24%-52%) in CR1, 7%
(95% CI, 1%-28%) in CR2w/CR1\1y, and 47%
(95% CI, 18%-72%) in CR2w/CR1$1y (Figure 1C).
In multivariate analysis, both the intensity of condi-
tioning and disease status at the time of transplantation
were independent predictors of LFS (Table 3). Recip-
ients of RIC had a 2.3-fold higher risk of relapse or
death compared to MAC recipients. The median
follow-up of survivors for RIC was 3.8 years and for
MAC 4.5 years (P 5 .4). The most frequent causes of
death after RIC (n 5 44) were relapse 61%, infection
22%, and GVHD 5%, whereas after MAC (n 5 19)
were relapse 32%, infection 36%, and GVHD 11%.
Relapse
The incidence of relapse at 3 years after RIC was
43% (95% CI, 31%-55%) and after MAC was 9%
(95% CI, 5%-18%; P\ .01) (Figure 2A). The overall
incidence of relapse for patients in CR1 was 30% (95%
CI, 19%-41%), in CR2w/CR1\1y was 48% (95%CI,
27%-69%) and in CR2 w/CR1$1y was 21% (95%CI,
3%-39%) (P 5 .08). In recipients of MAC the relapse
incidence in CR1 was 12% (95% CI, 0%-24%), in
CR2w/CR1\1y was 19% (95% CI, 0%-42%), and
in CR2w/CR1$1y was 13% (95% CI, 0%-33%)
(Figure 2B). In contrast, patients with RIC had relapse
incidence of 40% (95% CI, 25%-55%) in CR1, 71%
(95% CI, 21%-99%) in CR2w/CR1\1y, and 27%
(95% CI, 2%-52%) in CR2w/CR1$1y (Figure 2C).
Median time to relapse was 1.8 years in RIC and not
reached in theMACgroup. Inmultivariate analysis, af-
ter adjusting for disease status at transplantation, RIC
had a 4.7-fold higher risk of relapse compared toMAC
recipients (Table 3).
TRM
TRM at 2 years was similar in the 2 groups (19%
[95% CI, 10%-28%] in RIC versus 27% [95% CI,
14%-40%] in MAC, P 5 .5). Neither receiving
a TNC cell dose above or below the median
(21% [95% CI, 11%-31%] versus 23% [95% CI,







Neutrophil recovery at 42 days 94% (89%-99%) 82% (71%-93%) <.01
Platelet recovery at sixth month 68% (51%-85%) 67% (50%-84%) .30
Sustained donor engraftment 86% (78%-94%) 82% (71%-93%) .57
Grade II-IV acute GVHD 47% (35%-59%) 67% (51%-82%) <.01
Grade III-IV acute GVHD 16% (8%-24%) 31% (18%-44%) .05
Chronic GVHD 30% (19%-41%) 34% (19%-49%) .43
2-year TRM 19% (10-28%) 27% (14-40%) .55
Relapse at 3 years 43% (31%-55%) 9% (5%-18%) <.01
Leukemia-free survival at 3 years 31% (21%-43%) 55% (41%-70%) .02
CI indicates confidence interval; GVHD, graft-versus-host disease; TRM, transplant-related mortality.
Table 1. Demographics of UCB Recipients with AMLTreated with RIC or MAC HCT
Patient Characteristics
RIC MAC
P-valuen (%) n (%)
Number of patients 74 45 NA
Year of transplant
2001-2004 24 (32%) 11 (24%) .35
2005-2009 50 (68%) 34 (76%)
Age
#45 8 (11%) 45 (100%) <.01
Median 55 33
(range) (25-69) (19-43)
Preceding MDS or MPD 21 (28%) 2 (4%) <.01
Disease status
CR1 48 (65%) 25 (56%) .31
CR2w/CR1<1y 14 (19%) 11 (24%)
CR2w/CR1>51y 12 (16%) 9 (20%)
Cytogenetics
Favorable 3 (4%) 7 (16%) .14
Intermediate 31 (42%) 14 (31%)
Unfavorable 30 (41%) 17 (38%)
Unknown significance 5 (7%) 3 (7%)
Median time from diagnosis to transplant for
CR1 patients days (range)
128 (46-2861) 114 (67-230) .84
HCT-CI
0 18 (25%) 7 (16%) .13
1-2 18 (25%) 20 (44%)
$3 37 (50%) 17 (40%)
CMV seropositive recipient 43 (58%) 26 (58%) .97
TNC (107)/kg* 3.3 3.9 .32
Median (range) (0.2-6.3) (1.7-5.9)
CD34+ (105)/kg* 4.9 4.9 .34
Median (range) (1.3-12.9) (1.1-1.9)
CD3+ (106)/kg* 1.3 1.3 .96
Median (range) (0.4-2.6) (0.3-3.0)
HLA-matching†
4/6 38 (51%) 28 (62%) .47
5/6 25 (34%) 13 (29%)
6/6 11 (15%) 4 (9%)
ABO compatibility†
Matched 16 (22%) 8 (18%) .68
Minor mismatch 31(42%) 17 (38%)
Major mismatch 27 (36%) 20 (44%)
Number of units
1 11 (15%) 5 (11%) .56
2 63 (85%) 40 (89%)
Median follow-up of survivors years (range) 3.8 (0.6-8.5) 4.5 (0.7-8.5) .40
UCB indicates umbilical cord blood; RIC, reduced-intensity conditioning; MAC, myeloablative conditioning; HCT, hematopoietic stem cell transplanta-
tion; NA, not applicable; MDS, myelodysplastic syndrome; MPD, myeloproliferative disorder; CR1, first complete remission; CR2w/CR1<1y, second
complete remission with CR1 duration <1 year; CR2w/CR1>51y, second complete remission with CR1 duration $1 year; HCT-CI, hematopoietic
stem cell comorbidity index; CMV, cytomegalovirus; TNC, total nucleated cell dose; HLA, human leukocyte antigen.
*For double UCB recipients, the nucleated CD34+ and CD3+ cell doses reported are the combined dose of the UCB donor units.
†For double UCB recipients, HLA and ABO matching was defined by the worst matched of the 2 units.
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Figure 1. Leukemia-free survival of AML patients in first and second
complete remission (CR1-2) who underwent umbilical cord blood he-
matopoietic stem cell transplantation (A) after myeloablative condition-
ing (MAC) (——) versus reduced-intensity conditioning (RIC) (– – –);
(B) for patients receiving MAC or (C) RIC according to disease status
at the time of transplantation categorized as CR1 (——), CR2 with
CR1 $ 1 year (– – –) and CR2 with CR1\1 year (-----).
Biol Blood Marrow Transplant 17:1327-1334, 2011 1331Conditioning Intensity in AML after UCBT12%-34%], P 5 .75) nor a CD341 cell dose above or
below the median (22% [95% CI\12%-32%] versus
22% [95% CI, 14%-30%], P 5 .79) affected the inci-
dence of TRM. The incidence of TRM for patients
with HCT-CI score of 0, 1-2, or $3 was 17% (95%
CI, 2%-32%), 16% (95% CI, 4%-28%), and 29%
(95% CI, 14%-41%), respectively (P 5 .31). TRM
was also not significantly influenced by whether pa-
tients were transplanted in CR1 (22%, 95% CI,
12%-32%), CR2 w/CR1\1yr (20%, 95% CI, 4%-
36%) or CR2 w/CR1$1yr (24%, 95% CI, 6%-42%)(P 5 .99). No variables were independent predictors
of TRM in the multivariate model.
Hematopoietic Recovery
The incidence of neutrophil recovery at day 42 af-
ter RIC was 94% (95% CI, 89%-99%) at a median of
10 days (range: 5-39 days) and after MAC was 82%
(95% CI 71%-93%) at a median of 23 days (range:
13-38 days) (P \ .01). In contrast, the proportion
with full chimerism at day 21 among evaluable patients
(n5 105) after RIC was 20% (95%CI, 10%-30%) and
after MAC was 60% (95% CI, 45%-75%) (P\ .01);
the difference was no longer present at day 100 among
evaluable patients (n 5 85). The cumulative incidence
of platelet recovery $50,000/mL after RIC was 68%
(95% CI, 51%-85%) at a median time of 55 days
(range: 0-181 days) and after MAC was 67% (95%
CI, 50%-84%) at a median of 77 days (range: 42-177
days) (P 5 .30).
GVHD
The incidences of grade II-IV aGVHD after RIC
was 47% (95% CI, 35%-59%) and after MAC was
67% (95% CI, 51%-82%) (P\ .01). Similarly, the in-
cidence of grade III-IV aGVHD was lower after RIC
compared to MAC (Table 2). However, subgroup
analysis evaluating risk of grade II-IV aGVHD in re-
cipients of ATG versus no-ATG after RIC showed
lower incidence with ATG (27% [95% CI, 9%-45%]
versus 56% [95% CI, 41%-71%], P 5 .04). The 2-
year incidence of cGVHD was similar in RIC and
MAC recipients (30 [95% CI, 19%-41%] versus
34% [95% CI, 19%-49%], P 5 .43).DISCUSSION
We studied the effect of the intensity of the condi-
tioning regimen on the outcome of allogeneic trans-
plantation for patients with AML in CR1-2. The
main observations of our study were that (1) there
was a lower risk of relapse and superior LFS after
MAC, with similar TRM regardless of the intensity
of the conditioning regimen, (2) lower risk of aGVHD
after RIC, and (3) similar rates of sustained donor en-
graftment.
Although single center and registry data both sup-
port the use RIC in patients with AML [15-18,30-33],
to date there has been no randomized clinical trial
that has evaluated the impact of RIC compared to
MAC in outcomes for AML or other hematologic
malignancies. Our study is unique as it is focused on
recipients of UCB grafts with all patients receiving
a uniform conditioning regimen (within their
respective groups) and supportive care. Using
matched related donors (MRD), European Group
for Blood and Marrow Transplantation Group
Table 3. Multivariate Analysis of Outcomes




RIC 2.3 1.3-4.0 <.01
Disease status at HCT
CR1 1.0
CR2w/CR1<1y 1.9 1.0-3.4 .03




RIC 4.7 2.0-11.0 <.01
Disease status at HCT
CR1 1.0
CR2w/CR1<1y 1.9 1.0-3.8 .06




RIC 0.6 0.3-1.4 .24
Disease status at HCT
CR1 1.0
CR2w/CR1<1y 0.9 0.3-2.7 .86
CR2w/CR1$1y 1.1 0.4-3.1 .85
CI indicates confidence interval; MAC, myeloablative conditioning; RIC, reduced-intensity conditioning; HCT, hematopoietic stem cell transplantation;
CR1, first complete remission; CR2w/CR1<1y, second complete remission with CR1 duration <1 year; CR2w/CR1>51y, second complete remission
with CR1 duration $1 year.
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similar LFS after RIC in AML patients older than age
50 [16]. With matched unrelated donor (MUD), al-
though patients .50 years enjoyed similar risks of re-
lapse and LFS using either conditioning intensity, in
patients\50 years the relapse risk was increased after
RIC although LFS was similar [17]. Recently the
Center for International Blood and Marrow Trans-
plantation and Research (CIBMTR) compared the
outcomes after RIC versus MAC in patients with
AML and MDS patients transplanted with marrow
or peripheral blood from an unrelated or related do-
nor. They reported higher relapse incidence after
RIC and a marginally better LFS for those treated
with MAC [18]. These registry-based studies included
some patients with advanced or active leukemia, we in-
cluded only patients in CR1-2. Notably, in this cohort
transplanted with UCB, patients in CR1 and those in
CR2 with longer CR1 derived greater benefit after
RIC. In subgroup analysis of 24 CR2 patients with
short and long CR1 who received RIC, no difference
in patient and disease characteristics, including diag-
nostic cytogenetics, was observed (data not presented).
In this study, the risk of relapse after MAC UCB
HCT was relatively low (9% at 3 years), and compared
favorably to that of other donor sources [16,17].
Approximately 90% of our patients had 2 partially
HLA-matched UCB units, which was reported to have
an enhancedGVL effect in acute leukemia patients after
transplantation [34].Theuse ofmoremismatched grafts
in double UCB setting, KIR-ligand mismatching or in
vivo selection of the cord with the greater inherentimmune reactivity after 2UCBunitsmay be possible ex-
planations for this effect. On the other hand, the risk
with RIC (43% at 3 years) was not different from what
has been reported previously [7,16-17,35]. Preceding
MDS/MPD [36] and monosomal karyotype [23,29],
both of which have been shown to be associated with
poorer outcomes after HCT, were more frequent in
the RIC group and may have contributed to the higher
risk of relapse. In this retrospective study we had
insufficient molecular data to further define leukemia
phenotypes and the risk of relapse. Considering RIC
patient were older compared with MAC in our study,
it is possible that poor prognosis inherent with older
age could not be overcome by the GVL effect of RIC
UCB transplantation. On the other hand, with
a median follow-up time of 3.8 years, 3 year LFS of
31% represents an improvement when compared with
historic data using chemotherapy in older patients
[37-39]. Although a larger study is required to clarify
the risk factors yielding a higher risk of relapse after
RIC, comprehensive molecular and cytogenetic
evaluation and risk stratification at diagnosis in order
to consider high risk AML patients for allogeneic
transplantation in early remission may be warranted.
Our institutional defined age cutoff for offering RIC
rather than MAC UCB transplantation may need to be
revised, in particular for older patients who are in
good clinical condition and are likely to tolerate more
intensive therapy. Less clinically fit patients who are
poor candidates for MAC need to be counseled on the
relative risk benefit of RIC UCB early in the course of
their disease so that the opportunity to administer
Figure 2. Cumulative incidence of relapse for AML patients in first and
second complete remission (CR1-2) who underwent umbilical cord
blood (UCB) hematopoietic stem cell transplantation (HCT) (A) after
myeloablative conditioning (MAC) (——) versus reduced-intensity con-
ditioning (RIC) (– – –); (B) for patients receiving MAC or (C) RIC
according to disease status at the time of transplantation categorized
as CR1 (——), CR2 with CR1 $1 year (– – –), and CR2 with CR1
\1 year (-----).
Biol Blood Marrow Transplant 17:1327-1334, 2011 1333Conditioning Intensity in AML after UCBTpotentially curative therapy is not missed. Alternative
strategies such as higher intensity conditioning and/or
posttransplantation antileukemic therapy may be
considered for patients with high-risk leukemia who
had a short CR1.
We found that the time to neutrophil recovery was
shorter after RIC, but notably there was no difference
in the incidence of sustained donor engraftment be-
tween the 2 groups. We and other have previously
shown that UCB has sufficient numbers of immune
cells to reproducibly engraft after RIC [14,40-43].This observation demonstrates that concerns about
donor engraftment depending on the intensity of the
conditioning regimen should not be a factor limiting
an AML patient in remission from proceeding to
UCB transplantation.
In contrast to EBMT but similar to CIBMTR
analyses [18], we did not observe a significant differ-
ence for 2-year TRM between conditioning groups.
This result was seen despite the possible bias to select
older and less fit patients with comorbidities for RIC.
Thus, in our study, we achieved the goal of using RIC
to reduce toxicity and TRM for frail patients who
would not eligible for HCT otherwise.
In summary, MAC compared to RIC in AML pa-
tients resulted similar TRM and superior LFS with de-
creased risk of relapse in UCB HCT. Disease control
was especially poor for patients in CR2 with short C1
duration. Our study highlights the importance of con-
sidering older patients with high risk AML for UCB
transplantation in CR1 rather than in CR2 after a short
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